atp synthase inhibitor 1

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

mPTP-IN-1 (Compound 14e) is an inhibitor of the mitochondrial permeability transition pore (mPTP). By targeting the C subunit of ATP synthase, mPTP-IN-1 prevents calcium-induced opening of the mPTP. This compound is applicable in studies related to myocardial ischemia/reperfusion injury (IRI).

GSK-3β/HDAC-IN-1 (Compd 4) is a pioneering non-ATP competitive inhibitor that can penetrate the blood-brain barrier, targeting glycogen synthase kinase 3β/histone deacetylases (GSK-3β/HDACs). It exhibits IC50 values of 0.142 μM for GSK-3β, 0.03 μM for HDAC2, and 0.045 μM for HDAC6. GSK-3β/HDAC-IN-1 is utilized in Alzheimer's research.

SAR502250 is a potent, selective, ATP-competitive, orally active, and brain-penetrant GSK3 inhibitor with a human GSK-3β IC50 value of 12 nM, exhibiting antidepressant-like activity and being researched for potential application in Alzheimer's disease (AD) treatment.

Mtb ATP synthase-IN-1 (compound 6ab) is a potent inhibitor of Mycobacterium tuberculosis (Mtb) ATP synthase (MIC = 0.452-0.499 μg/mL) [1] that can be used in anti-mycobacterium research, showing low cytotoxicity (Vero IC 50 > 64 μg/mL) and acceptable oral bioavailability with good metabolic stability.

ATP synthase inhibitor 2 is an inhibitor of Pseudomonas aeruginosa ATP synthase (IC₅₀ = 10 μg/mL) that completely inhibits ATP synthesis activity in Pseudomonas aeruginosa at a concentration of 128 μg/mL.

Oligomycin A (MCH 32) is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

ATP Synthase Inhibitor 2 (Compound 22) TFA is a potent inhibitor of Pseudomonas aeruginosa ATP synthase with an IC50 value of 10 μg/mL. It effectively halts ATP synthesis in Pseudomonas aeruginosa at a concentration of 128 μg/mL [1].